solute carrier family 29 member 4Genealiases: ENT4 · PMAT
Q-omics provides the consensus-scored SLC29A4 profile across patient tissues and cancer cell-line models. SLC29A4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC29A4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SLC29A4 RNA expression shows 18,029 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where SLC29A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC29A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC29A4 survival associations across molecular data types. SLC29A4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC29A4 RNA expression–survival associations across cancer types. High SLC29A4 expression shows unfavorable associations in ACC, UVM, MESO, COAD and LIHC, but favorable associations in LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC29A4 RNA expression.
This table summarizes SLC29A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC29A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC29A4 shows lower tumor expression in THCA and higher tumor expression in KIRC, LUAD, KICH, LUSC and UCEC. The KIRC box plot shows higher SLC29A4 RNA expression in tumor versus normal tissue (log2 FC = +2.780, t-test p < 0.001).
This table shows molecular features associated with SLC29A4 in patient tissues and cancer cell lines. In patient samples, SLC29A4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC29A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
